Success Stories and Challenges Ahead in Hematopoietic Stem Cell Gene Therapy: Hemoglobinopathies as Disease Models
- 18 October 2021
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 32 (19-20) , 1120-1137
Abstract
Gene therapy is a relatively novel field that amounts to around four decades of continuous growth with its good and bad moments. Currently, the field has entered the clinical arena with the ambition to fulfil its promises for a permanent fix of incurable genetic disorders. Hemoglobinopathies as target diseases and hematopoietic stem cells (HSCs) as target cells of genetic interventions had a major share in the research effort toward efficiently implementing gene therapy. Dissection of HSC biology and improvements in gene transfer and gene expression technologies evolved in an almost synchronous manner to a point where the two fields seem to be functionally intercalated. In this review, we focus specifically on the development of gene therapy for hemoglobin disorders and look at both gene addition and gene correction strategies that may dominate the field of HSC-directed gene therapy in the near future and transform the therapeutic landscape for genetic diseases.Keywords
This publication has 88 references indexed in Scilit:
- Chicken HS4 Insulators Have Minimal Barrier Function Among Progeny of Human Hematopoietic Cells Transduced With an HIV1-based Lentiviral VectorMolecular Therapy, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Genotoxic Potential of Lineage-specific Lentivirus Vectors Carrying the β-Globin Locus Control RegionMolecular Therapy, 2009
- Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal HemoglobinMolecular Therapy, 2009
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Journal of Clinical Investigation, 2008
- Foamy virus vectors: The usefulness of a perfect parasiteGene Therapy, 2008
- In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- HIV-1 Integration in the Human Genome Favors Active Genes and Local HotspotsCell, 2002
- A 5′ element of the chicken β-globin domain serves as an insulator in human erythroid cells and protects against position effect in DrosophilaCell, 1993